

Laurent Savale

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5680192/laurent-savale-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

88
papers

3,945
citations

31
h-index

62
g-index

101
ext. papers

5,494
ext. citations

9.6
avg, IF

5.23
L-index

#	Paper	IF	Citations
88	WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension.. <i>European Respiratory Review</i> , 2022 , 31,	9.8	3
87	Sequential combination therapy with parenteral prostacyclin in BMPR2 mutations carriers.. <i>Pulmonary Circulation</i> , 2022 , 12, e12023	2.7	
86	Post-acute COVID-19 syndrome.. <i>European Respiratory Review</i> , 2022 , 31,	9.8	11
85	Screening for pulmonary arterial hypertension in adults carrying a mutation. <i>European Respiratory Journal</i> , 2021 , 58,	13.6	11
84	External validation of a refined 4-strata risk assessment score from the French pulmonary hypertension Registry. <i>European Respiratory Journal</i> , 2021 ,	13.6	4
83	Double-lung transplantation followed by delayed percutaneous repair for atrial septal defect-associated pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2021 ,	13.6	0
82	The isobaric pulmonary arterial compliance in pulmonary hypertension. <i>ERJ Open Research</i> , 2021 , 7,	3.5	1
81	Prevalence of pulmonary embolism in patients with COVID-19 at the time of hospital admission. <i>European Respiratory Journal</i> , 2021 , 58,	13.6	22
80	Four-Month Clinical Status of a Cohort of Patients After Hospitalization for COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 325, 1525-1534	27.4	152
79	Outcomes of patients with decreased arterial oxyhaemoglobin saturation on pulmonary arterial hypertension drugs. <i>European Respiratory Journal</i> , 2021 , 58,	13.6	2
78	Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 204, 842-854	10.2	13
77	Five-year survival after an acute episode of decompensated pulmonary arterial hypertension in the modern management era of right heart failure. <i>European Respiratory Journal</i> , 2021 , 58,	13.6	1
76	Pulmonary Hypertension in Patients with Common Variable Immunodeficiency. <i>Journal of Clinical Immunology</i> , 2021 , 41, 1549-1562	5.7	2
75	Different cardiovascular and pulmonary phenotypes for single- and double-knock-out mice deficient in BMP9 and BMP10. <i>Cardiovascular Research</i> , 2021 ,	9.9	7
74	Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension. <i>Cardiovascular Research</i> , 2021 , 117, 1391-1401	9.9	5
73	Chronic thromboembolic pulmonary hypertension and totally implantable central venous access systems. <i>European Respiratory Journal</i> , 2021 , 57,	13.6	3
72	Characteristics and Long-term Outcomes of Pulmonary Venocclusive Disease Induced by Mitomycin C. <i>Chest</i> , 2021 , 159, 1197-1207	5.3	5

71	Cardiovascular disorders in patients with congenital portosystemic shunts: 23 years of experience in a tertiary referral centre. <i>Archives of Cardiovascular Diseases</i> , 2021 , 114, 221-231	2.7	2
70	Our current understanding of and approach to the management of lung cancer with pulmonary hypertension. <i>Expert Review of Respiratory Medicine</i> , 2021 , 15, 373-384	3.8	
69	Reversible pulmonary hypertension associated with multivisceral Whipple's disease. <i>European Respiratory Journal</i> , 2021 , 57,	13.6	
68	Acute Right-Heart Failure in Patients with Chronic Precapillary Pulmonary Hypertension 2021 , 301-316		
67	Cardiovascular phenotypes predict clinical outcomes in sickle cell disease: An echocardiography-based cluster analysis. <i>American Journal of Hematology</i> , 2021 , 96, 1166-1175	7.1	1
66	A CELSR1 variant in a patient with pulmonary arterial hypertension. <i>Clinical Genetics</i> , 2021 , 100, 771-772	4	0
65	Transplantation for pulmonary arterial hypertension with congenital heart disease: Impact on outcomes of the current therapeutic approach including a high-priority allocation program. <i>American Journal of Transplantation</i> , 2021 , 21, 3388-3400	8.7	2
64	Pulmonary hypertension associated with busulfan. <i>Pulmonary Circulation</i> , 2021 , 11, 20458940211030170	2.7	1
63	Serum and pulmonary uric acid in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2021 , 58,	13.6	6
62	Lung transplantation for sarcoidosis: outcome and prognostic factors. <i>European Respiratory Journal</i> , 2021 , 58,	13.6	14
61	Phenotype and Outcomes of Pulmonary Hypertension Associated with Neurofibromatosis Type 1. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 202, 843-852	10.2	4
60	Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors. <i>European Respiratory Journal</i> , 2020 , 56,	13.6	11
59	Pumpless Lung Assist as a Bridge to Medical Therapy in a Teenager With Pulmonary Arterial Hypertension and Partial Anomalous Pulmonary Venous Return. <i>Canadian Journal of Cardiology</i> , 2020 , 36, 1831.e7-1831.e9	3.8	4
58	Phenotype and outcome of pulmonary arterial hypertension patients carrying a mutation. <i>European Respiratory Journal</i> , 2020 , 55,	13.6	11
57	Portopulmonary hypertension in the current era of pulmonary hypertension management. <i>Journal of Hepatology</i> , 2020 , 73, 130-139	13.4	28
56	Rapid onset honeycombing fibrosis in spontaneously breathing patient with COVID-19. <i>European Respiratory Journal</i> , 2020 , 56,	13.6	23
55	Glucocorticoids with low-dose anti-IL1 anakinra rescue in severe non-ICU COVID-19 infection: A cohort study. <i>PLoS ONE</i> , 2020 , 15, e0243961	3.7	7
54	Pulmonary Hypertension in Sickle Cell Disease: Current Controversies and Clinical Practices. <i>Respiratory Medicine</i> , 2020 , 123-134	0.2	1

53	Intensity and quality of exertional dyspnoea in patients with stable pulmonary hypertension. <i>European Respiratory Journal</i> , 2020 , 55,	13.6	16
52	Risks and outcomes of gastrointestinal endoscopy with anaesthesia in patients with pulmonary hypertension. <i>British Journal of Anaesthesia</i> , 2020 , 125, e466-e468	5.4	1
51	Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation. <i>European Respiratory Journal</i> , 2020 , 56,	13.6	57
50	Neutralization of CXCL12 attenuates established pulmonary hypertension in rats. <i>Cardiovascular Research</i> , 2020 , 116, 686-697	9.9	25
49	Congenital portosystemic shunts: Vascular liver diseases: Position papers from the francophone network for vascular liver diseases, the French Association for the Study of the Liver (AFEF), and ERN-rare liver. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020 , 44, 452-459	2.4	3
48	Glucocorticoids with low-dose anti-IL1 anakinra rescue in severe non-ICU COVID-19 infection: A cohort study 2020 , 15, e0243961		
47	Glucocorticoids with low-dose anti-IL1 anakinra rescue in severe non-ICU COVID-19 infection: A cohort study 2020 , 15, e0243961		
46	Glucocorticoids with low-dose anti-IL1 anakinra rescue in severe non-ICU COVID-19 infection: A cohort study 2020 , 15, e0243961		
45	Glucocorticoids with low-dose anti-IL1 anakinra rescue in severe non-ICU COVID-19 infection: A cohort study 2020 , 15, e0243961		
44	French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	82
43	Screening for pulmonary arterial hypertension in systemic sclerosis. <i>European Respiratory Review</i> , 2019 , 28,	9.8	21
42	Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. <i>Lancet Respiratory Medicine</i> , 2019 , 7, 594-604	35.1	61
41	Pulmonary arterial hypertension populations of special interest: portopulmonary hypertension and pulmonary arterial hypertension associated with congenital heart disease. <i>European Heart Journal Supplements</i> , 2019 , 21, K37-K45	1.5	8
40	Clinical phenotypes and outcomes of precapillary pulmonary hypertension of sickle cell disease. <i>European Respiratory Journal</i> , 2019 , 54,	13.6	8
39	Therapeutic effect of pirfenidone in the sugen/hypoxia rat model of severe pulmonary hypertension. <i>FASEB Journal</i> , 2019 , 33, 3670-3679	0.9	14
38	Selective BMP-9 Inhibition Partially Protects Against Experimental Pulmonary Hypertension. <i>Circulation Research</i> , 2019 , 124, 846-855	15.7	48
37	Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	75
36	Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era. <i>European Respiratory Review</i> , 2018 , 27,	9.8	13

35	Central versus peripheral cannulation of extracorporeal membrane oxygenation support during double lung transplant for pulmonary hypertension. <i>European Journal of Cardio-thoracic Surgery</i> , 2018 , 54, 341-347	3	22
34	Pulmonary vascular endothelium: the orchestra conductor in respiratory diseases: Highlights from basic research to therapy. <i>European Respiratory Journal</i> , 2018 , 51,	13.6	68
33	Lung transplantation for scleroderma lung disease: An international, multicenter, observational cohort study. <i>Journal of Heart and Lung Transplantation</i> , 2018 , 37, 903-911	5.8	45
32	Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease. <i>Journal of Heart and Lung Transplantation</i> , 2018 , 37, 647-655 ⁵⁸	5.8	31
31	Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2018 , 137, 693-704	16.7	92
30	Clinical and Hemodynamic Correlates of Pulmonary Arterial Stiffness in Incident, Untreated Patients With Idiopathic Pulmonary Arterial Hypertension. <i>Chest</i> , 2018 , 154, 882-892	5.3	7
29	Ectopic upregulation of membrane-bound IL6R drives vascular remodeling in pulmonary arterial hypertension. <i>Journal of Clinical Investigation</i> , 2018 , 128, 1956-1970	15.9	87
28	Macrophage Migration Inhibitory Factor (MIF) Inhibition in a Murine Model of Bleomycin-Induced Pulmonary Fibrosis. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	12
27	Chronic blood exchange transfusions in the management of pre-capillary pulmonary hypertension complicating sickle cell disease. <i>European Respiratory Journal</i> , 2018 , 52,	13.6	15
26	Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2018 , 52,	13.6	37
25	Impact of High-Priority Allocation on Lung and Heart-Lung Transplantation for Pulmonary Hypertension. <i>Annals of Thoracic Surgery</i> , 2017 , 104, 404-411	2.7	15
24	Long-term outcome in liver transplantation candidates with portopulmonary hypertension. <i>Hepatology</i> , 2017 , 65, 1683-1692	11.2	40
23	Portopulmonary Hypertension. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017 , 38, 651-661	3.9	16
22	Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	69
21	Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	62
20	Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	298
19	Acute decompensated pulmonary hypertension. <i>European Respiratory Review</i> , 2017 , 26,	9.8	28
18	De-novo donor-specific anti-HLA antibodies 30 days after lung transplantation are associated with a worse outcome. <i>Journal of Heart and Lung Transplantation</i> , 2016 , 35, 1067-77	5.8	54

17	Loss of Vascular Distensibility During Exercise Is an Early Hemodynamic Marker of Pulmonary Vascular Disease. <i>Chest</i> , 2016 , 149, 353-361	5.3	46
16	Genetic counselling in a national referral centre for pulmonary hypertension. <i>European Respiratory Journal</i> , 2016 , 47, 541-52	13.6	63
15	Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity. <i>European Respiratory Journal</i> , 2016 , 48, 1517-1519	13.6	36
14	Initial dual oral combination therapy in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2016 , 47, 1727-36	13.6	85
13	Criteria for diagnosis of exercise pulmonary hypertension. <i>European Respiratory Journal</i> , 2015 , 46, 728-37	13.6	154
12	Clinical pharmacology of endothelin receptor antagonists used in the treatment of pulmonary arterial hypertension. <i>American Journal of Cardiovascular Drugs</i> , 2015 , 15, 13-26	4	19
11	Pulmonary arterial hypertension in patients treated with interferon. <i>European Respiratory Journal</i> , 2015 , 46, 1851-3	13.6	9
10	Pulmonary Hypertension Complicating Fibrosing Mediastinitis. <i>Medicine (United States)</i> , 2015 , 94, e1800	1.8	32
9	Chemotherapy-induced pulmonary hypertension: role of alkylating agents. <i>American Journal of Pathology</i> , 2015 , 185, 356-71	5.8	116
8	Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. <i>European Respiratory Journal</i> , 2014 , 43, 1691-7	13.6	214
7	Pulmonary arterial hypertension in patients treated with interferon. <i>European Respiratory Journal</i> , 2014 , 44, 1627-34	13.6	66
6	Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension. <i>European Respiratory Journal</i> , 2013 , 41, 96-103	13.6	75
5	Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. <i>Journal of Heart and Lung Transplantation</i> , 2012 , 31, 150-8	5.8	73
4	Pulmonary arterial hypertension in patients treated by dasatinib. <i>Circulation</i> , 2012 , 125, 2128-37	16.7	448
3	A hemodynamic study of pulmonary hypertension in sickle cell disease. <i>New England Journal of Medicine</i> , 2011 , 365, 44-53	59.2	354
2	Portopulmonary hypertension: survival and prognostic factors. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 178, 637-43	10.2	175
1	Right heart failure	32-47	